Table 5.
Risk factors for Infectious Diseases Society of America/American Thoracic Society Guideline – discordant initial antibiotic selection
| Guidelines Concordance (n = 54) |
Guidelines Discordance (n = 40) |
p-value | |
|---|---|---|---|
| Age, y | 68.5 ± 15.9 | 71.3 ± 19.6 | .44 |
| Gender (Female) | 28 (51.8) | 9 (22.5) | .004* |
| Severe community-acquired pneumonia | 24 (44.4) | 26 (65) | .048* |
| Comorbid conditions: | |||
| None | 17 (31.5) | 9 (22.5) | .5 |
| Single | 22 (40.7) | 16 (40) | |
| Multiple | 15 (27.8) | 15 (37.5) | |
| Prior antibiotic therapya | 20 (37) | 23 (57.5) | .049* |
| ECOG ≥2b | 28 (51.8) | 26 (65) | .2 |
| Enteral tube feeding | 2 (3.7) | 7 (17.5) | .03* |
| Healthcare–associated pneumonia | 11 (20.4) | 19 (47.5) | .005* |
| Pleural effusion | 11 (20.4) | 0 | .002* |
| Initial antibiotic treatment: | |||
| Nonantipseudomonas β-lactams | 42 (77.8) | 10 (25) | <.001* |
| Antipseudomonas β-lactams | 3 (5.6) | 24 (60) | <.001* |
| Macrolide | 43 (79.6) | 2 (5) | <.001* |
| Quinolone | 11 (20.4) | 5 (12.5) | .31 |
Data are presented as mean ± SD or n (%), unless otherwise stated
aPrior antibiotic therapy: systemic antibiotic use in the 90 days prior to this admission. bECOG scale: Eastern Cooperative Oncology Group scale of performance status. *Statistically significant difference